Home Immunology & Inflammation Peroxidases inhibitor - Interleukins inhibitor - TNF-alpha inhibitor - NF-κB inhibitor - AMPK activator Demethyleneberberine

research use only

Demethyleneberberine Peroxidases inhibitor

Cat.No.S3299

Demethyleneberberine (DMB), a component of Cortex Phellodendri Chinensis (CPC), significantly alleviates the weight loss and diminishes myeloperoxidase (MPO) activity, while significantly reduces the production of pro-inflammatory cytokines, such as interleukin (IL)-6 and tumor necrosis factor-α (TNF-α), and inhibits the activation of NF-κB signaling pathway. This compound potentially ameliorates NAFLD (Non-alcoholic fatty liver disease) by activating AMPK pathways.
Demethyleneberberine Peroxidases inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 324.35

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S329901 DMSO]3 mg/mL]false]]]false]]]false Purity: 99.01%
99.01

Chemical Information, Storage & Stability

Molecular Weight 324.35 Formula

C19H18NO4

 Storage (From the date of receipt) 3 years -20°C powder
CAS No. 25459-91-0 -- Storage of Stock Solutions

Synonyms DMB Smiles COC1=C(OC)C2=C[N+]3=C(C=C2C=C1)C4=CC(=C(O)C=C4CC3)O

Solubility

In vitro
Batch:

DMSO : 3 mg/mL (9.24 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
NF-κB [1]
MPO [1]
IL-6 [1]
TNF-α [1]
IL-1β [1]
IL-6 [1]
COX-2 [1]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04785326 Completed
Moderate to Severe Chronic Plaque Psoriasis
Dong-A ST Co. Ltd.|Meiji Seika Pharma Co. Ltd.
 April 28 2021 Phase 3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.